Enterprise Value

408.2M

Cash

329.9M

Avg Qtr Burn

-26.27M

Short % of Float

4.04%

Insider Ownership

38.50%

Institutional Own.

38.65%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
EXS73565 (‘565) Details
Cancer, B-cell malignancies, Chronic lymphocytic leukemia

Phase 1/2

Initiation

Phase 1/2

Initiation

Phase 1

Data readout

Phase 1

Update

EXS21546 (A2A receptor antagonist) Details
Cancer, Non-small cell lung carcinoma, Renal cell carcinoma

Failed

Discontinued